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This study sought to identify novel CD8+ T cell homing markers by studying acute
graft versus host disease (aGvHD), typically involving increased T cell homing to the
skin and gut. FACS-sorted skin-homing (CD8β+/CLA+), gut-homing (CD8β+/integrinβ7+),
and reference (CD8β+/CLA–/integrinβ7–) T cells were compared in patients affected by
cutaneous and/or gastrointestinal aGVHD. Microarray analysis, qPCR, and flow cytome-
try revealed increased expression of peptidase inhibitor 16 (PI16) in skin-homing CD8+
T cells. Robust association of PI16 with skin homing was confirmed in all types of aGvHD
and in healthy controls, too. PI16 was not observed on CLA+ leukocytes other than
T cells. Induction of PI16 expression on skin-homing T cells occurred independently
of vitamin D3. Among skin-homing T cells, PI16 expression was most pronounced in
memory-like CD45RO+/CD127+/CD25+/CD69−/granzyme B− cells. PI16 was confined to
the plasma membrane, was GPI-anchored, and was lost upon restimulation of memory
CD8+ T cells. Loss of PI16 occurred by downregulation of PI16 transcription, and not by
Phospholipase C (PLC)- or Angiotensin-converting enzyme (ACE)-mediated shedding, or
by protein recycling. Inhibitor screening and pull-down experiments confirmed that PI16
inhibits cathepsin K, but may not bind to other skin proteases. These data link PI16 to
skin-homing CD8+ T cells, and raise the possibility that PI16 may regulate cutaneous
cathepsin K.
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Introduction
Precise regulation of CD8+ T cell homing to distinct tissues is a
prerequisite for mounting immune responses against pathogens
that have narrow tissue tropism. It is well established that regula-
tion of T-cell homing utilizes complex regulatory circuits involving
unique combinations of chemokines and adhesion molecules, each
identifying different tissues for circulating T cells. Homing is heav-
ily implicated in the maintenance of immunity against antigen
challenge occurring in different anatomical compartments, espe-
cially in barrier tissues, such as the gut and the skin [1]. On the
other hand, T-cell homing to distinct anatomical compartments is
also involved in the development of several immunologic disorders
or adverse immune reactions restricted to given tissues or organs.
This has been demonstrated in multiple animal models and human
clinical studies, among others in ulcerative colitis (UC) [2, 3],
multiple sclerosis (MS) [4, 5], Crohn’s disease (CD) [6, 7], and
has also been suggested to be involved in acute graft versus host
disease (aGvHD). We believe that aGvHD is of particular interest
in terms of CD8+ T-cell homing to the gut and skin, for several
reasons.
Acute GvHD is one of the most frequent, potentially fatal,
short-term adverse events of allogeneic hematopoietic stem cell
transplantation (aHSCT) [8]. The disease is typically associated
with massive, graft-mediated cytotoxic tissue damage, character-
istically restricted to a limited set of organs, typically to the skin
and the gut [9, 10]. Notably, some patients suffer from either
cutaneous or gastrointestinal (GI) aGvHD, while others display
both manifestations simultaneously. Tissue damage in both cuta-
neous and GI aGvHD occurs upon invasion of the skin and gut
by CD8+ T cells [9] displaying canonical skin-homing (CLA+)
and gut-homing integrinβ7+ (ITGβ4β7+) phenotypes, respectively
[11, 12]. It has been shown that rapid shifts in the numbers of
these activated subsets in the blood of aHSCT patients precede
the two forms of the disease, and hence may be of diagnostic and
prognostic value [11–13]. Furthermore, proof of concept studies
showed that blockade of CD8+ T cell homing pathways may allevi-
ate respective tissue damage in mouse models of aGVHD [14, 15].
Indeed, current phase 1 and phase 2 clinical trials with two
monoclonal antibodies, vedolizumab and natalizumab, targeting
ITGβ4 or ITGβ4β7, approved for the treatment of UC/CD and
CD/MS, respectively, are currently exploring whether the same
approach may work for the treatment of GI aGVHD in humans, as
well [16, 17]. Although less well documented, there is some evi-
dence that the homing preferences of activated CD4+ Th and Treg
cells are also altered in aGvHD. Activated CD4+ Th cells become
enriched in damaged organs [18]. In contrast, Treg cells home to
tissues affected by aGvHD in diminished numbers [19, 20].
Taken together, aHSCT patients diagnosed with cutaneous
and/or GI aGvHD provide a unique opportunity for the in-depth
comparison of naturally activated human CD8+ T cells homing to
the gut and skin, for several reasons: (i) in aGvHD, CD8+ T cells
home to both the skin and the gut, enabling a direct comparison of
the two cell types in the same human disease, without the skewing
effect of different disease states, (ii) these phenomena may occur
simultaneously, enabling the comparison of these cells within the
same host, (iii) CD8+ T cells actively home to these organs and
are not only attracted by local inflammation, (iv) full maturation
of skin and gut-homing effector CD8+ T cells takes place, and
(v) effector mechanisms mediated by skin- and gut-homing CD8+
T cells are fundamental to the disease process.
In this study, we compared skin-and gut-homing CD8+ T cells
of aGvHD patients by gene expression profiling, flow cytometry,
and functional bioassays, and confirmed our findings on CD8+
T cells of healthy blood donors, as well. We propose that a novel
marker, peptidase inhibitor 16 (PI16), is associated with the skin-
homing CD8+ T cell subset in both aGVHD patients, and healthy
individuals. Based on these results, we propose that PI16 is linked
to human skin-homing T cells in both inflammatory and steady-
state conditions.
Results
Skin-homing CD8+ T cells overexpress PI16 mRNA in
patients affected by aGvHD
Skin- and gut-homing CD8+ T cell subsets were isolated from
four groups of aHSCT patients developing (i) cutaneous aGvHD,
(ii) GI aGvHD, (iii) both cutaneous and GI aGvHD simulta-
neously, or (iv) none (see Supporting Information Table 1
for detailed patient information). PBMCs of aHSCT patients





R©–/CD8β+/CLA–/ITGβ7– cytotoxic T cell subsets
by three-way FACS sorting (Fig. 1A). Next, skin-homing, gut-
homing, and reference CD8+ T cells were analyzed by compar-
ative gene expression profiling. Transcriptome analysis revealed
62 genes differentially expressed between the three CTL subsets
(Fig. 1B, two-way repeated measures [RM] ANOVA with false
discovery rate [FDR] <0.01, see Supporting Information Table 2
for detailed results). As gene set enrichment analysis was unable
to identify known gene sets differentially expressed depending
on CTL homing preferences (p > 0.05), we next set out to ana-
lyze individual genes. Among the most significant differences, we
selected PI16 for further analysis (Fig. 1B, marked with asterisk
to the right) based on others’ earlier publications [21, 22].
PI16 expression is a hallmark feature of skin-homing
CD8+ T cells regardless of organ involvement in
aGvHD
Microarray data suggested that PI16 mRNA showed more than
nine times higher expression in skin-homing CD8β+/CLA+ T cells
than in gut-homing, or reference CTLs of aHSCT patients (Fig. 2B,
one-way RM ANOVA, p < 0.0001). We analyzed whether this phe-
nomenon was restricted to any of the four patient groups, that is,
linked to any given type of CTL-mediated organ damage in aGvHD,
or GvHD in general (Fig. 2B). We found that overexpression
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Figure 1. Comparative gene expression profiling of skin-homing, gut-homing, and reference CD8+ T cells of aHSCT patients developing no aGvHD,
cutaneous aGvHD, gastrointestinal GvHD, or both aGvHD manifestations simultaneously. (A) Gating strategy and representative three-way FACS
sorting of gut-homing Ly/Live/CD8β/ITGβ7+, skin-homing Ly/Live/CD8β/CLA+, and reference Ly/Live/CD8β/ITGβ7–/CLA– cytotoxic T cells, isolated
from PBMCs of aHSCT patients. Numbers indicate percent gated cells. One experiment representative of five independent experiments with
n = 4 donors for each group, n = 20 donors total. (B) FACS-sorted gut-homing, skin-homing, and reference cytotoxic T cells (as indicated at the
top) of aHSCT patients developing no aGvHD, cutaneous aGvHD, intestinal aGvHD, or both aGVHD manifestations simultaneously (as indicated
at the bottom), analyzed by gene expression profiling (n = 5 for each possible T cell subset/disease group combination). Heatmap displays 62
differentially expressed genes, identified by two-way RM ANOVA (FDR< 0.01), analyzing sources of variance introduced by CD8+ T cell homing
subsets, respective organ damage, and possible interactions between these two factors. Columns represent individual samples; rows correspond to
genes. Colors display expression below (pale blue), or above (dark blue) the mean. For clarity’s sake, data shown are centered and SD-normalized.
To the right, asterisk marks peptidase inhibitor 16 (PI16). Combined results of three independent experiments with n = 4, n = 8, and n = 8 donors
for each group, n = 20 total.
of PI16 by skin-homing CLA+ CD8+ T cells occurred in all four
patient groups (Fig. 2B, two-way RM ANOVA, p < 0.0001)
regardless of the type of organ involvement in aGVHD (p > 0.05).
In addition, the data suggested that PI16 overexpression was not
restricted to aGVHD, as aHSCT patients with no aGvHD also dis-
played increased expression of PI16 in skin-homing CD8+ T cells.
These results were also confirmed by qPCR (Fig. 2C, 2D two-way
RM ANOVA, p < 0.0001). Flow cytometry also confirmed that
PI16 protein positive cells were enriched in the CLA+ subset (on
average 10.9-times) compared with reference CTLs (Fig. 2E–G).
Furthermore, PI16+ cells were significantly more frequent (on
average 5.2-times) among skin-homing than among gut-homing
CD8+ T cells (Fig. 2E, two-way RM ANOVA, p = 0.0004). This
observed pattern held true in all patient groups regardless of
the type of organ involvement (Fig. 2F, two-way RM ANOVA,
p = 0.9388), which is in line with the RNA data. Again, observed
organ damage did not appear to have an influence on the pattern of
PI16 expression (Fig. 2F, two-way RM ANOVA, p = 0.9204), even
if, in the cutaneous aGvHD group, between-subset comparisons
did not reach formal significance (Fig. 2F, p = 0.2266, p = 0.4859,
respectively). These observations conclusively suggested that
PI16 is associated with skin-homing CD8+ T cells, the expression
of which may be largely independent of the development of
aGvHD, or the exact type of organ involvement in aGvHD.
Robust association of PI16 protein with skin-homing
CD8+ T cells in both health and disease
As the expression of PI16 appeared to be independent of aGvHD,
we next went on to test whether aHSCT was required at all for
the induction of PI16 expression on skin-homing T cells. To this
end, we analyzed skin-homing, gut-homing, and reference CTLs
of healthy blood donors in a similar fashion. We found PI16
expression patterns matching those observed in aHSCT, with even
more pronounced differences of PI16 expression between cell
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Figure 2. Testing the link among PI16, CD8+ T cell homing subsets, and aGvHD organ involvement by microarray gene expression profiling, qPCR,
and flow cytometry. (A, C, and E [top]) PI16 expression in skin-homing CD8β/CLA+, gut-homing CD8β/ITGβ7+, and reference CD8β/ITGβ7–/CLA–
cytotoxic T cells of aHSCT patients, as analyzed by microarray, qPCR, and flow cytometry, respectively (n = 15 each, median) is shown. One-way RM
ANOVA with FDR correction; stars indicate significance in pairwise comparisons: ***p < 0.001 (B, D and F [bottom]) PI16 expression among the same
three cytotoxic T cell subsets, also accounting for possible differences introduced by CD8+ T cell-mediated organ damage, that is, in patients with
no aGvHD, cutaneous aGvHD, intestinal aGvHD, or both manifestations of aGvHD. (n = 5 for each possible T cell subset/disease group combination;
box and whiskers plots with median). Two-way RM ANOVA with FDR correction; stars indicate significance in pairwise comparisons: *p < 0.05,
**p < 0.01, ***p < 0.001. (G [far right] representative flow cytometry data of a single patient). Numbers indicate percent gated cells. Combined results
of three experiments with n = 4, n = 8, and n = 8 donors for each group, n = 20 total.
subsets among healthy individuals compared with aHSCT patient.
On average, 63% of the skin-homing T cells of healthy blood
donors stained positive for PI16 protein; 13.3-times more than
gut-homing T cells (4.74%), and 7.5-times more than reference
(8.43%) CTLs (Fig. 3A, two-way RM ANOVA, p < 0.0001). These
data suggested that the presence of PI16 on skin-homing T cells is
a distinctive feature of this subset in both health and disease, that
is, it is not restricted to, or induced by either aGvHD or aHSCT.
Also, it was apparent that the difference is more pronounced
among healthy individuals, than in aHSCT patients (irrespective
of them being affected by, or remaining free of aGvHD). For these
reasons, we used healthy donors for the further analysis of PI16.
PI16 is a marker associated with skin-homing CD8+
T cells but not other CLA+ leukocytes
Considering that CLA is frequently expressed by a wide variety of
leukocytes beside CD8+ T cells, we first sought to clarify if PI16
expression is linked to CLA expression, or if it is a restricted fea-
ture typical to skin-homing T cells. Flow cytometry confirmed that
PI16 over-expression was restricted to CLA+ T CD8+ and CD4+
T cells, as CLA+ monocytes or NK cells expressing CLA did not
display PI16 in appreciable numbers (Fig. 3B). This suggests that
expression of PI16 is not mechanistically linked to that of CLA in
various leukocytes; but instead, PI16 is specifically linked to skin-
homing T cells. We also found that within the skin-homing CD8+
T cell subset, PI16 positive cells were more frequently CD45RO+,
CD127+, CD25+, CD69–, and granzyme B cells (Fig. 3C), than
their PI16 negative counterparts, while there was no difference in
the case of some other CD8+ T cell markers (IFN-γ, CD40L, not
shown). These data indicate that PI16 production is most intense
in memory-like, resting skin-homing CD8+ T cells and is less char-
acteristic for recently activated effector cytotoxic T cells actively
producing effector molecules. Finally, we tested if PI16 expression
was maintained in skin-homing T cells after entering the human
skin, like that of CLA [23], or became downregulated upon enter-
ing the target organ, like in the case of integrinβ4 on gut-homing
T cells [24]. We found that PI16-expressing CD8+ CLA+ T cells can
be found in the healthy human skin (Fig. 4). Spatial distribution
of PI16 in the skin was similar to others’ earlier observations [25]:
that is, weak or absent in the epidermis, scattered in the dermis.
We found that scattered dermal PI16 positivity showed clear colo-
calization with cutaneous CD8+/CLA+ T cells (Fig. 4).
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Figure 3. Evaluation of PI16 as a marker associated with skin-homing
CLA+ T cells of healthy individuals. (A) Frequency of PI16 positive cells
among skin-homing CD8β/CLA+, gut-homing CD8β/ITGβ7+, and refer-
ence CD8β/ITGβ7–/CLA– cytotoxic T cells of healthy blood donors. Gating
strategy and representative data for each analyzed cytotoxic T cell sub-
set are shown to the left. One-way RM ANOVA with FDR correction is
shown to the right (one experiment, n = 7, median): stars indicate signif-
icance in pairwise comparisons: ***p < 0.001. (B) PI16 expression in dis-
tinct PBMC subsets expressing the canonical skin-homing T cell marker
CLA; typical patterns of PI16 expression in CLA+ blood cytotoxic T cells,
CLA+ helper T cells, CLA+ NK cells, and CLA+ monocytes of healthy
blood donors (n = 3, representative data). (C) Comparative analysis of
PI16− and PI16+ skin-homing CD8+ T cells of healthy blood donors
(n = 6, box and whiskers plot with median). Paired t-test: **p < 0.01
and ***p < 0.001. Each panel shows one experiment representative of
six (panel A) or two (panels B and C).
Figure 4. Spatial distribution of PI16 protein and skin-resident CD8+
T cells in the skin. Analysis of the localization of CD8+ skin-homing
T cells and PI16 in healthy human skin. (A and B) Phase contrast and
composite fluorescent images of a representative human skin section
analyzed by immunohistochemistry is shown. (C) Selected regions of (B)
sections I–II represent dermal, sections III–IV epidermal staining with
DAPI, CD8-, CLA-, and PI16-specific antibodies, as indicated. Shown are
results of one experiment representative of four, one sample each.
Skin-homing CD8+ T cells display a
membrane-bound, GPI-anchored PI16 protein
PI16 is a protein with largely unknown functions that, originally,
was described as a soluble serum protein released by prostate
cells [26]. However, it has been reported that the protein may
appear on the surface of Treg cells [22], and this is also in line
with our flow cytometry data. By performing confocal microscopy
on sorted CD8+ T cells, we found that the majority of PI16 protein
in CD8+ T cells were indeed confined to the plasma membrane
(PM), showing a similar distribution to, but no clear colocaliza-
tion with, CLA (Fig. 5A), within the PM. Recently, it has been
confirmed that PI16 protein expressed by murine fibroblasts is
GPI-anchored [27]. To test the means of PI16 linkage to the PM
of human CD8+ T cells, we exposed CD8+ T cells to a bacterial
PI-PLC, capable of detaching GPI-anchored proteins from the PM.
We found that upon exposition of CD8β+/PI16+ T cells to PI-
PLC, PI16+ staining showed a rapid, dose-dependent reduction
(Fig. 5B), similar to that of CD59, a known GPI-anchored protein,
but unlike CD8β, which does not have a GPI anchor, and hence
remained unaffected. These data demonstrate that human skin
homing CLA+ T cells express a membrane bound, GPI-anchored
form of PI16.
C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2018. 48: 1944–1957 Tissue immunology and leukocyte trafficking 1949
Figure 5. Analysis of the subcellular distribution of PI16 protein in skin-
homing CD8β+ T cells. (A) Analysis of the subcellular localization of
PI16 in skin-homing CD8+ T cells. Phase contrast, monochrome, and
three-color fluorescent microscopy of MACS-sorted CD8+ T cells are
shown. Blue, CD8; green, CLA; and red, PI16. Representative subcellular
distribution of PI16 in a typical, skin-homing, CD8β+/CLA+/PI16+ T cell
is displayed in the cell at the center. One experiment representative of
three independent experiments. (B) Investigation of human PI16 as a
possible GPI-anchored PM protein of T cells. Assessing cell surface PI16
signal after PI-PLC-mediated in vitro digestion of GPI-anchors. CD59
(a known GPI-anchored PM protein) and CD8β (having no GPI anchor)
serve as positive and negative controls, respectively. Numbers indicate
percent positivity of T cells upon exposure to various concentrations of
PI-PLC, as shown. One experiment representative of two independent
experiments.
Induction of PI16 occurs independently of canonical
pathways imprinting the skin-homing phenotype
We next analyzed whether known mechanisms responsible for
imprinting the skin- and gut-homing phenotype in activated näıve
CD8+ T cells could also invoke or suppress PI16 expression on
these cells. In two seminal papers, it was shown that exposure of
in vitro activated blood CD8+ T cells to DC-released vitamin D (D3)
and retinoic acid (RA) was capable of inducing some (although
not all) skin- and gut-homing markers, respectively, in a mutu-
ally exclusive fashion [28, 29]. Using this approach, we found
that although D3 and RA were capable of affecting expression
of the skin-homing markers CLA (Fig. 6A, two-way RM ANOVA,
p = 0.0049) and CCR10 on activated CD8+ T cells (Fig. 6B, two-
way RM ANOVA, p = 0.0015), PI16 remained unaffected by D3
and RA, only reacting on T-cell activation (Fig. 6C). We next tested
whether expression of PI16 on skin-homing T cells may be induced
independently of DC-mediators, for example, by local epithelia. It
has been suggested that skin epithelial cells may imprint activated
skin-homing T cells to express CLA and CCR8 via soluble medi-
ators that reach skin-draining lymph nodes and activated T cells
via afferent lymphatics [30]. Considering this evidence, we ana-
lyzed if indirect coculture of CD8+ T cells during their activation
with live skin explants and gut organoids, containing live epithe-
lia, promotes or inhibits PI16 expression. We found that coculture
of CD8+ T cells with skin explants provided some support for
the induction of a skin-homing phenotype in terms of CLA and
CCR8 expression, partly in an activation-dependent manner (Fig.
6D). However, PI16 expression was not promoted by cocultivation
with skin explants (Fig. 6D, two-way RM ANOVA, p > 0.05). Also,
expression of PI16 remained unaffected by the presence of intesti-
nal organoids (Fig. 5E, two-way RM ANOVA, p > 0.05). Hence,
induction of PI16 on skin-homing CD8+ T cells seems to be inde-
pendent of known factors inducing other skin-homing CD8+ T cell
biomarkers, and particularly those affecting CLA expression.
Skin-committed CD8+ T cells maintain PI16
expression until their activation
As PI16 expression was most typical for skin-homing, non-näıve,
memory-like CD45RO+/CD8+ T cells (Fig. 3C), and stimulation of
peripheral PI16+ T cells resulted in rapid downregulation of this
marker (Fig. 6C), we next tested whether reactivation of memory-
like T cells leads to loss of PI16. We found that reactivation
of CD45RO+ T cells by a-CD3/CD28 led to an almost complete
elimination of PI16 from the cell surface within 48 h (Fig. 7A,
two-way RM ANOVA, p = 0.0002). In marked contrast, PI16
was barely present on bona fide näıve CD45RO−/CD8+ T cells,
and did not react to activation either (Fig. 7A). Next, we tested
the mechanism of PI16 removal from the surface of reactivated
skin-homing memory-like CD8+ T cells. Considering (i) that bac-
terial PLC was capable of detaching PI16 from the surface of skin-
homing T cells and (ii) that PLC activation is an inherent compo-
nent of T cell activation, we hypothesized that activation of the
PLC pathway in T cells may be responsible for the removal of PI16
from the cell surface upon activation. Hence, we tested whether
(i) inhibition of PLC activity by U-73122, (ii) inhibition of the
angiotensin-converting enzyme, another possible GPI-removing
enzyme by captopril, [31, 32], or (iii) inhibition of possible endo-
cytic recycling of PI16 by Dynasore could inhibit loss of PI16 from
the cell surface upon activation. We observed that loss of PI16
upon a-CD3/CD28 treatment could not be inhibited by PLC- or
ACE-inhibitors, or by stopping endocytic protein recycling either
(Fig. 7B). On the other hand, we found that skin-homing CD8+
T cells ceased to express PI16 mRNA post activation, closely fol-
lowed by the loss of the protein from the PM (Fig. 7C). Overall,
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Figure 6. Investigation of the induction of PI16 expression in skin-homing CD8β+ T cells. (A–C) Impact of vitamin D3 (D3) and retinoic acid (RA)
treatment on the expression of the canonical skin-homing markers CLA (panel A) and CCR10 (panel B), versus on that of PI16 (panel C) after ex vivo
activation of peripheral blood CD8+ T cells with a-CD3/CD28 (n = 3, mean with SEM). Gating strategy and representative results obtained on days
0 and 4 are shown below. Results of one experiment representative of two experiments. (D) Expression of skin-homing markers CLA and CCR8,
and that of PI16 on activated CD8+ T cells after 4 days long coculture with skin organoids (n = 3, mean with SEM) One experiment representative
of two. (E) Expression of CLA, the gut-homing marker integrin β7 (ITGβ7), and PI16 on activated CD8+ T cells upon 4 days of coculture with gut
organoids (n = 3, mean with SEM). One experiment performed. For clarity, all bar charts display percent PI16 positivity compared to day 0 untreated
controls as reference. Results of FDR-corrected two-way RM ANOVA are shown with stars indicating significance in pairwise comparisons: *p < 0.05,
**p < 0.01, ***p < 0.001.
these data suggest that reactivated skin-committed CD8+ memory-
like T cells lose PM-bound PI16 by transcriptional downregulation,
and not due to protein shedding or increased recycling of the pro-
tein from the PM.
PI16 acts as a partial inhibitor of cathepsin K
Typically, reactivation of CD8+/CLA+/CD45RO+, skin-homing
memory T cells occurs within the human skin, where a large
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Figure 7. Analysis of the termination of PI16 expression in skin-homing CD8+/CD45RO+ T cells. (A) PI16 protein expression of healthy blood
donors’ CD8β+/CD45RO+ and CD8β+/CD45RO– T cells before, and at various time points after ex vivo activation by anti-CD3/CD28 (n = 3, mean
with SEM). Two-way RM ANOVA with FDR correction: *p < 0.05, **p < 0.01, ***p < 0.001 in pairwise comparisons. (B) Flow cytometry analyzing PI16
expression upon anti-CD3/CD28 treatment in the absence and presence of U-73122 (inhibitor of PLC-mediated shedding of GPI-anchored proteins),
captopril (inhibition of ACE-mediated shedding), or Dynasore (inhibition of endocytic protein recycling, n = 3; mean with SEM). (C) Kinetics of PI16
mRNA expression upon a-CD3/28-mediated activation of CD8β+ T cells as assessed by qPCR (n = 3, mean with SEM). FDR-corrected one-way RM
ANOVA: in pairwise analyses, stars indicate significance: **p < 0.01. Each dataset represents one experiment of two performed.
number of proteases, involved in various inflammatory processes
and pathologies, are present [33, 34]. Considering that PI16 is a
largely unknown, rather putative, peptidase inhibitor, we tested
whether human PI16 was capable of suppressing the activity of
skin proteases. Earlier it was suggested that mouse PI16 may sup-
press murine cathepsin K [27], and that PI16 may inhibit MMP-
2 [35]. Our protease inhibitor assays (Fig. 8) demonstrated that,
in line with others’ mouse data, human PI16 is a partial inhibitor
of human cathepsin K (Fig. 8A). Human PI16 has an IC50 compa-
rable to synthetic inhibitors, but in line with others’ findings made
in a murine system, it is not able to achieve full enzymatic inhibi-
tion [27]. On the other hand, at least in our hands, human PI16 did
not affect human MMP-2 activity (Fig. 8B). To further corroborate
these findings, and also to identify other skin proteases possibly
interacting with PI16, we next performed pull-down assays uti-
lizing PI16 as a bait to find its partners in human skin protein
lysates. Comparative analysis of the flow-through and the pulled
down protein fractions showed that PI16 did not display high affin-
ity against a large number of skin proteases, that is, cathepsins A,
D, V, X, Z, P, kallikreins 5, 10, 11, CD26 (dipeptidyl peptidase-4),
and MMP-2 (Fig. 8C), as none of them were specifically enriched
in the pulled-down fraction, or depleted from the flow-through
by PI16. Taken together, these data suggest that human PI16 on
skin-homing T cells may act as a partial inhibitor of cathepsin K
in the human skin, but may not bind to other skin proteases with
high affinity.
Discussion
This study shows that by analyzing human patients diagnosed
with aGvHD, further insight may be gained into the mechanisms
regulating cutaneous and GI CD8+ T cell homing. Our data suggest
that PI16 is a novel protein marker displaying robust association
with the skin-homing CD8+ T cell phenotype in both health and
disease.
PI16 was first described as a protein released into the blood
serum by prostate cells, and originally designated as prostate
secretory protein 94-binding protein due to its high affinity for
PSP94 [26]. It soon became clear that PI16 was expressed by
multiple other, unrelated cell types, too, and the protein became
incorporated into the CAP (cysteine-rich secretory proteins,
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Figure 8. Testing human PI16 as an inhibitor of human matrix metalloprotease-2, cathepsin K, and other skin proteases involved in skin home-
ostasis and cutaneous inflammation. (A and B) Relative activity of human cathepsin K (CTSK) and matrix metalloprotease-2 (MMP-2), respectively,
in the presence of various concentrations of potent synthetic inhibitors and recombinant human PI16. Half-maximal inhibitory concentration
(IC50), calculated by nonlinear regression, is shown in log10M concentration. Shown are the results of one experiment out of two for both CTSK
and MMP-2, each data point representing a mean of duplicates. (C) Pull-down assay utilizing PI16-covered beads as baits, and PI16-free beads as
controls performed to identify other human skin proteases selectively binding to recombinant human PI16. Distribution of various skin proteases
in the pull-down versus the flow-through fractions in both cases, as analyzed by proteome profiling arrays. One experiment representative of two,
one sample each.
antigen 5, and pathogenesis-related 1 proteins) superfamily [36].
All CAP proteins feature a highly conserved CAP domain,
but they are rather heterogeneous due to additional, highly
variable protein domains, which allow them to exert multiple,
independent biological functions. These include involvement of
CAP proteins into endocrine and paracrine regulation, regula-
tion of matrix reorganization, but also fertilization, signaling,
immunomodulation, and host defense.
Nevertheless, the function of the highly conserved core domain,
the CAP domain itself, is poorly understood, and hence the com-
mon function of such proteins is still a matter of speculation [37].
This issue becomes critical in the case of PI16, as it consists of
nothing but the signature CAP domain and a rather long hinge
region. Without solid knowledge on the function of CAP domains,
deciphering the function(s) of PI16 remains challenging. In this
regard, the hinge region itself is not particularly helpful either, as
it lacks similarity to any known protein domains. Even though its
very end is rich in hydrophobic amino acids, it has no confirmed
intramembrane or intracellular domains [36]. Based on sequence
analysis of the hinge, existence of a GPI anchor attached to the end
of PI16 has been first suspected [26], then confirmed, in mice [27],
but so far, not in humans. Based on sequence homology, PI16 was
hypothesized to act as a protease inhibitor, and in line with this,
it has been proposed that PI16 suppresses cathepsin K [27] and
MMP-2 activity [35]. So far, these activities have only been shown
by studying murine cardiomyocytes and human cardiac endothe-
lium, respectively, and have not been confirmed in humans or
by independent research groups. To sum up, the exact biological
roles and the functional properties of the CAP domain, most CAP
family members, also including PI16, have, until now, remained
largely obscure [36, 37].
This study demonstrates that human skin-homing CD8+ T cells
display a GPI-anchored, PM-bound form of PI16, and that PI16
expression is most pronounced in the CD45RO+ memory compart-
ment. Interestingly, earlier observations of others have already
provided some, albeit very circumstantial, evidence supporting
the notion that PI16 may be linked to cutaneous homing of T cells.
Among the extremely limited number of papers published on
PI16, one has shown that PI16 is expressed by Tregs responding
to CCL17 [22]. This is relevant to our findings because CCL17
is recognized by CCR4, which is a chemokine receptor on many
skin-homing T cells. There is a large body of evidence confirming
the involvement of CCL17 and CCR4 homing of T cells to the skin,
especially under inflammatory conditions [38, 39], and mostly
within the non-näıve (effector/memory) T cell compartment [40].
Further corroborating this concept, in another paper, a genome-
wide association study identified a polymorphism within the PI16
gene that predisposed to chronic skin inflammation [21].
We found that in healthy blood donors, the majority of
CD8+/CLA+ T cells expressed PI16, which was in sharp contrast
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with the scarce PI16 positivity observed on other, CD8+/CLA−
T cell subsets. However, expression of PI16 was neither complete
within the skin-homing T cell subset, nor was it exclusive to the
skin-homing phenotype. In short, PI16 is clearly associated to T cell
homing, but it has limited sensitivity and specificity as a marker
of all skin-homing T cells. We found that PI16 expression was
most characteristic for non-näıve CD45RO+, memory-like skin-
homing CD8+ T cells, and was less typical for recently activated
(CD69+ and Granzyme B+) effector cells homing to the skin. In
addition, expression of PI16 was tightly controlled, and became
virtually eliminated by CD45RO+ CD8+ T cells upon their reac-
tivation in vitro. Collectively, these data suggest that within the
non-näıve CD8+ T cell compartment, PI16 expression may be less
typical for recently activated, or reactivated, cells exerting effector
functions. Interestingly, differences in PI16 expression in health
and disease also suggested that PI16 expression became less pro-
nounced once skin-homing T cells had been activated. As judged
by flow cytometry, PI16 expression of skin-homing CD8+ T cells
was most prominent in healthy blood donors (having limited num-
bers of activated skin-homing CD8+ T cells), was less pronounced
in aGvHD (polyclonal CD8+ T cell activation), and was even less
prominent in active cutaneous aGvHD (widespread activation of
skin-homing CD8+ T cells).
We also showed that PI16 disappeared from activated CD8+
T cells by means of transcriptional downregulation, and not by GPI
anchor digestion and subsequent protein shedding. These obser-
vations may allow speculation that the PI16 function(s) associated
to skin-homing T cells are not related to release of this putative
peptidase inhibitor into the extracellular space. They rather sug-
gest that the function(s) of PI16 become(s) either dispensable or
detrimental upon cognate activation of skin-homing CD8+ T cells
in the skin, for example, in cutaneous immune responses requiring
local CTL intervention.
In this regard, it is interesting that both MMP-2 and cathepsin
K, the two proposed targets of PI16 action, are critically involved in
the regulation of skin tissue homeostasis. MMP-2 is an extracellu-
lar protease and the altered activity of MMP-2 has sweeping conse-
quences for the skin; MMP2 alters both the availability and activity
of a plethora of signaling ligands and adhesion molecules affecting
cutaneous integrity and local inflammation [41]. Cathepsin K, on
the other hand, being capable of collagen and elastin digestion, is
also linked to skin inflammation, matrix reorganization, and scar
formation both as an intracellular lysosomal enzyme [42], and as
a secreted, extracellular protease [43]. We found that similar to
murine data, human PI16 was capable of interfering with human
cathepsin K activity, acting as a partial inhibitor in the submicro-
molar range. However, in our hands, recombinant PI16 was not
able to suppress MMP-2 activity or pull-down MMP-2 from skin
lysates, which conflicts others’ observations and hence the role of
PI16 as a regulator of MMP-2 will need further analysis.
Taken together, our data indicate that resting human skin-
homing CD8+ T cells are instructed to display PI16, and maintain
its expression until their reactivation. The possibility that reac-
tivation of skin-committed CD8+ CLA+ T cells may suppress an
inhibitor (PI16) of a cutaneous inflammatory protease (cathep-
sin K) is intriguing. This observation may allow speculation that
during T cell-mediated cutaneous immune responses, cutaneous
CD8+ T cells may affect skin homeostasis by stopping inhibition
of select inflammatory proteases. Nevertheless, a more complete
understanding of the role of PI16 in this context needs further
studies, particularly studies focusing on the exact function of the




Human skin and intestinal biopsies were obtained from patients
of the Department of Dermatology, Venereology and Derma-
tooncology, Budapest, Hungary, and the Uzsoki Hospital of the
Semmelweis University, Budapest, Hungary, respectively. Biopsies
were retrieved following IRB-approved protocols, after obtaining
informed consent from all involved patients. Sections of biopsies
used were evaluated by pathologists and declared disease-free.
Blood samples
Blood samples were collected from selected aHSCT patients
(n = 20, see Supporting Information Table 1) of the Department
of Hematology and Stem Cell Transplantation, St. Istvan and St
Laszlo Hospital, Budapest, Hungary for research purposes, after
obtaining informed consent and IRB approval. aHSCT patients
belonging to the following groups were recruited: (i) patients
developing no acute GvHD following aHSCT, (ii) aHSCT patients
with acute cutaneous GvHD, (iii) aHSCT patients with acute GI
GvHD, or (iv) aHSCT patients with both acute and GI aGvHD
(see Supporting Information Table 1 for details, n = 5 each).
Samples from aHSCT patients without acute GvHD were collected
after ca. 30 days post aHSCT (no GvHD group). Samples from
aHSCT patients with aGvHD were collected at the time of diag-
nosis, before any GvHD-specific treatment had been commenced
(GvHD groups). In addition, control blood samples were also col-
lected from healthy volunteers, as well (n = 10).
PBMC isolation
Peripheral blood was collected by venipuncture in VACUETTE
R©
Acid Citrate Dextrose (ACD-A) tubes (BD Biosciences, San Jose,
CA). Samples were stored and transported at room temper-
ature (RT). PBMCs were isolated by density centrifugation
using Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) over
LeucoSepTM centrifuge tubes (Greiner Bio-One, Kremsmünster,
Austria). Median PBMC yield was 1.3 × 106 PBMC/mL blood; cell
viability was >95% by trypan blue exclusion. Within 2.5 ± 0.5 h
of venipuncture, cells were frozen in 90% FBS/10% DMSO using a
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Mr. Frosty freezing container (Thermo Fisher Scientific, Waltham,
MA) at −80°C and transferred to liquid nitrogen until further use.
FACS sorting
FACS sorting was used to isolate skin- and gut-homing
CD8+ T cells for microarray gene expression profiling. Frozen
PBMC samples were thawed as described elsewhere [44]
and immediately stained with LIVE/DEAD
R©
Fixable Dead
Cell Stain Near-IR (Thermo), anti-human CD8β-APC, anti-
human Cutaneous Lymphocyte Antigen (CLA)-FITC, and anti-
human Integrin β7 (ITGβ7)-PE antibodies (all from BD).
Three-way sorting of PBMCs was done on a BD FACSAria
III sorter. Skin-homing Ly/LIVE/DEAD
R©–/CD8β+/CLA+ T cells,
gut-homing Ly/LIVE/DEAD
R©–/CD8β+/ ITGβ7+ T cells, and
Ly/LIVE/DEAD
R©–/CD8β+/CLA–/ITGβ7– T cells, the latter serving
as reference, were acquired with the help of the FACSDiva soft-
ware (BD). Viability of sorted T cells was >95% by LIVE/DEAD
R©
staining. T cells were sorted directly into RLT Plus lysis buffer
(Qiagen, Valencia, CA); and the cell lysates were subsequently
frozen at −80°C.
Microarray gene expression profiling
Total RNA was extracted from FACS-sorted CD8+ T cell subsets
using the RNeasy Plus Micro Kit (Qiagen). Sample integrity and
yield were assessed on a 2100 Bioanalyzer using an RNA 6000
Pico Kit (Agilent Technologies, Santa Clara, CA). Three-thousand
picograms of total RNA per sample was amplified in two rounds
and Cy3-labeled by the Arcturus RiboAmp HS PLUS, Cy3 label-
ing Kit (Thermo). Cy3-labeled amplified cRNA was hybridized
to human GE 4x44K v2 whole-genome microarrays (Agilent)
and scanned on an Agilent Microarray Scanner. Raw data were
retrieved with the Feature Extraction software (Agilent). Batch
effect was removed by distance weighted discrimination [45].
Analyzes were performed using the BRB-ArrayTools developed by
Dr. Richard Simon and the BRB-ArrayTools Development Team.
The following genes were excluded from further analyzes: genes
flagged as not detected, genes displaying batch adjusted signal
intensities lower than log2 = 1, genes not detected in all samples of
any experimental groups, and genes not displaying twofold change
in at least one experimental group in either direction from the
given gene’s median value. The remaining gene set (1981 genes)
was analyzed by two-way RM ANOVA and Benjamini-Hochberg
multiple testing correction (FDR < 0.01) to identify differentially
expressed genes. Microarray data have been deposited at GEO
under accession number GSE103569.
qPCR
Total RNA was extracted and reverse transcribed from FACS-
sorted T cell subsets as above. PI16 gene expression was assessed
with human PI16-specific TaqMan probes and HGPRT as inter-
nal reference. cDNA was amplified on a 7900HT Fast Real-Time
PCR machine (Thermo) using 2× Sensifast Probe HI-ROX mas-
ter mix (Bioline, Taunton, MA). Results were calculated using the
comparative CT (CT) method.
Flow cytometry
For flow cytometry, cells were stained with anti-human CLA-FITC,
IFN-γ-FITC, integrinβ7-PE, PI16-PE, CCR10–PE, CCR4–PE, CCR8-
PE, CD8β–APC, CD8β-PECy7, CD3-APC, CD59-FITC, CD14 PerCP-
Cy5.5, CD56-APC (BD), granzyme-B–FITC, CD69–FITC (Biole-
gend, San Diego, CA), CD127–FITC, CD25–PerCP-eFluor710,
CD45RO PerCP-eFluor710 (Thermo), anti-human PI16-APC anti-
bodies (Miltenyi Biotec, Bergisch Gladbach, Germany), and appro-
priate isotype controls following standard protocols, as indicated.
Intracellular antigens were stained using Brefeldin-A and Fixa-
tion/Permeabilization Solution (BD). Cells were analyzed on a
FACSCalibur flow cytometer (BD). Data were evaluated using the
FlowJo v10.1 software (Treestar, Ashland, OR).
MACS sorting
MACS sorting was applied for all CD8+ T cell studies other than
gene expression profiling. CD8+ T cells were isolated from PBMCs
of healthy blood donors using anti-human CD8β APC antibodies
(BD) and anti-APC multisort microbeads. Magnetic cell sorting
was done on an AutoMACS Pro cell sorter, using the posselds pro-
gram (Miltenyi Biotec). APC-multisort microbeads were released
from sorted cells before any downstream assays have been com-
menced with.
Immunocytochemistry
MACS-sorted CD8β+ T cells were blocked with mouse and rat sera
(Sigma-Aldrich) and stained with anti-human CLA–FITC, PI16–
PE, and CD8β-APC antibodies (BD). For APC detection, signal
amplification was done using anti-APC-biotin and Streptavidin-
APC (Biolegend). After staining, cytospin slides were prepared,
and samples were covered with Fluoroshield, with DAPI histology
mounting media (Sigma-Aldrich) overnight, at RT. Images were
taken on an FV500 inverted laser scanning confocal microscope
(Olympus, Center Valley, PA) at 60× magnification. Image analy-
sis was performed with the Image J v. 1.8.0 112 software.
Immunohistochemistry
FFPE tissue sections (5 μm) were prepared from healthy human
skin biopsies. Antigen retrieval was done in sodium citrate buffer
(pH 6.0) at  +105°C for 30 min. Samples were blocked with 10%
FBS and stained with rat anti-human CLA-FITC (1:10, BD), mouse
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anti-human CD8a (1:50, Santa Cruz, Dallas, TX), and rabbit anti-
human PI16 (1:100, Novus, Littleton, CO) antibodies. Secondary
antibodies used were anti-mouse IgG-eFluor570 (1:100 Thermo)
and anti-rabbit IgG-APC (1:100, Thermo). Staining controls were
done by omitting primary antibodies. Images were captured with
an inverted confocal microscope (Olympus FV500) at 20× mag-
nification and evaluated with Image J v. 1.8.0 112.
GPI anchor digestion
MACS-sorted CD8β+ T cells were washed twice with PBS, and
1 × 106 cells/500 μL were left untreated or exposed to various
doses of Bacillus cereus PI-PLC (Thermo), as indicated, for 1 h at
RT. Cells were immediately stained and analyzed by flow cytom-
etry, as indicated.
RA and 1,25-dihydroxivitamin D3 treatment
MACS-sorted CD8β+ T cells were seeded on 24-well plates at a
density of 7 × 105 cells/well, in glutamine-supplemented RPMI
1640 (Thermo), 10% human serum type AB, 1× Glutamax, 1%
penicillin/streptomycin (Sigma-Aldrich). Culture media and sera
were pretested for assay performance in pilot studies. Cells were
activated with Dynabeads CD3/CD28 (Thermo) at a cell:bead
ratio of 1:3 for 2 days in the presence of 2.5 ng/mL recombinant
human IL-12 (Thermo). After 2 days, cultures were supplemented
with recombinant 12.5 ng/mL IL-2 (Thermo), split into three and
treated with 10−8 M RA, 10−8 M 1,25-dihydroxivitamin D3 (D3)
(Sigma-Aldrich), or vehicle only (0.1% ethanol). Every 2 days till
day 10 post activation, cultures were split into two, supplemented
with fresh chemicals and media, and analyzed by flow cytometry.
Coculture of activated CD8+ T cells with skin explants
and intestinal organoids
CD8+ T cell isolates were obtained and activated as above and
maintained in the lower chambers of 24 well 0.4 μm pore size tran-
swell plates. CD8+ T cells obtained from a single donor were split
in four, and were either (i) left untreated, (ii) activated only, (iii)
cocultivated with explants/organoids only, or (iv) activated and
also cocultured with explants/organoids. For CD8+ T cell cocul-
ture with skin explant cultures, healthy skin biopsies were cut into
three to four pieces and transferred to the upper chamber of the
transwell plates on day 2. Fifty microliter of RPMI 1640 (Thermo),
10% human serum type AB, and 1% pen/strep (Sigma-Aldrich)
were added to the upper chamber of each well, and skin biop-
sies were maintained at the air–liquid interphase for four further
days. For CD8+ T cell coculture with intestinal organoids, healthy
colon samples were processed as described elsewhere [46], with
minor modifications. Briefly, colonic crypts were isolated by resus-
pension of colon biopsies with a cold 2 mM EDTA release buffer.
Isolated crypts were embedded in 40 μL matrigel (Corning, Corn-
ing, NY) and transferred to the upper chamber of transwell plates
as above. After the matrigel sealed the chamber, 400 μL/well
culture medium, consisting of advanced DMEM/F-12, 5% FBS,
1× Glutamax, 1 × N-2, 1 × B-27 (all from Thermo), 10 mM
HEPES, pen/strep, 1 mM acetylcysteine, 500 nM A-83-01, 10 μM
SB202190, 10 nM [Leu15]-Gastrin I (all from Sigma-Aldrich)
50 ng/mL h EGF, 100 ng/mL h noggin, 100 ng/mL m Wnt3 A (all
from Peprotech, London, UK), and 500 ng/mL h R-Spondin1 (R&D
Systems, Minneapolis, MN) was added on top of the solidified
matrigel, and organoids were maintained for four further days.
Every 2 days till day 4 post activation, explant/organoid media
was replaced, T cell cultures were split into two, supplemented
with fresh chemicals and media, and analyzed by flow cytometry.
Pull-down assay and proteome profiling
Human skin samples, obtained as above, were immediately trans-
ferred to a ProteoJet Mammalian Cell Lysis Reagent, (Thermo)
supplemented with HaltTM Protease Inhibitors Cocktail (Thermo)
and preincubated at +4°C for 30 min. Next, subcutaneous fat was
removed and samples were cut in 1–3 mm pieces by sterile scalpels
and homogenized with a Diax 100 homogenizer (Heidolph,
Schwabach, Germany). Debris were removed by centrifugation.
Skin lysates were stored at −80°C until further use. For protein
pull down, 10 μg recombinant GST-tagged human PI16 (Abnova,
Taipei, Taiwan) was dialyzed using Slide-A-LyzerTM Dialysis Cas-
settes (Thermo). After removal of excess glutathione, PI16 was
bound to glutathione-linked agarose beads of the PierceTM GST
Protein Interaction Pull-Down Kit (Thermo). Pull-down assay was
performed with 100 μg skin protein lysate, following the manufac-
turer’s instructions. Proteome profiling was used to compare the
following fractions in a pair-wise manner: (i) specific pull-down
fraction (PI16-bound agarose beads), (ii) aspecific binding control
(empty agarose beads), (iii) whole skin lysate before pull down,
(iv) flow-through fraction after pull down. Skin proteases specifi-
cally bound to PI16 in pull-down assays were identified using Pro-
teome ProfilerTM Human Protease Array Kits (R&D). PI16-bound
skin proteases were identified by comparing the specific pull-down
fraction with the aspecific binding control, and the whole skin
lysate with the flow-through, respectively. Sample preparation,
membrane incubation, and signal detection were all carried out
following the manufacturer’s instructions. Densitometry was done
using the FluorChem Alphaview software (Alpha Innotech, San
Leandro, CA).
Protease inhibitor assays
Protease inhibitor assays were carried out using 25 μg recombi-
nant GST-tagged human PI16 (Abnova) protein, predialyzed on
Slide-A-LyzerTM Dialysis Cassettes (Thermo). Various dilutions
of dialyzed PI16 peptide, as indicated, were tested as putative
inhibitors of cathepsin K and MMP-2 using a Cathepsin K Inhibitor
Screening Kit and an MMP2 Inhibitor Screening Assay Kit,
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respectively (both from Abcam, Cambridge, UK). Assays were
done in duplicates, following the manufacturer’s instructions.
Cathepsin K assays were evaluated on a Labsystems Luminoskan
reader (Thermo). Results of MMP-2 assays were obtained using
a Labsystems Multiskan MS spectrophotometer (Thermo).
Statistical analysis
Statistical analysis was done using BRB Array Tools (microarray
results) or the Graphpad software (all other analyses). Two-way
RM ANOVA, one-way RM ANOVA, and paired t-tests were used
together with Benjamini–Hochberg FDR-correction for multiple
testing and pairwise comparisons, as needed. Unless otherwise
stated, p < 0.05 (t-tests) or FDR <0.05 (all other tests) was con-
sidered statistically significant.
General laboratory operation and raw data
accessibility
These studies were conducted in an ISO 9001:2015-certified lab-
oratory that operates under exploratory research principles. All
studies were performed using standard operating protocols and
research assays. FACS sorting and flow cytometry was performed
following the Guidelines for the use of flow cytometry and cell
sorting in immunological studies [47]. Methodology and results
of T-cell assays were described in accordance with the MIATA
guidelines [48]. Raw data can be provided per request.
Acknowledgments: This work was supported by the Hungarian
National Research, Development and Innovation Office (OTKA
K 116340, OTKA-NN 118018), by the ÚNKP-17-3-III-SE-22 New
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